Management of acute agitation in psychosis: An evidence-based approach in the USA

Advances in Psychiatric Treatment

Volumn 17, Issue 2, 2011, Pages 91-100

  Schleifer, Justin J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLONAZEPAM; DIAZEPAM; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; OLANZAPINE; PLACEBO; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGGRESSION; AGITATED BEHAVIOR SCALE; AGITATION; AKATHISIA; BEHAVIOR MODIFICATION; BIPOLAR MANIA; BRADYCARDIA; CARDIOPULMONARY DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSTONIA; EMPATHY; EVIDENCE BASED MEDICINE; EVOLUTION; EXCESSIVE SEDATION; HEART DISEASE; HOSTILITY; HUMAN; HUMAN RELATION; HYPOTENSION; IMMOBILIZATION; KIDNEY DISEASE; MONOTHERAPY; OVERT AGITATION SEVERITY SCALE; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRACTICE GUIDELINE; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT; STANDING; SYNCOPE; TACHYCARDIA; TREATMENT CONTRAINDICATION; UNITED KINGDOM; UNITED STATES;

EID: 79952266787     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.109.007310     Document Type: Review

References (78)

1. Abdelmawla N, Mitchell A (2006) Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms. Advances in Psychiatric Treatment 12: 35-44. (Pubitemid 43091931)
2. Aleman A, Kahn RS (2001) Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. European Neuropsychopharmacology 11: 289-93. (Pubitemid 32781008)
3. Allen MH (2000) Managing the agitated psychotic patient: a reappraisal of the evidence. Journal of Psychiatry 61 (suppl 14): 11-20.
4. Altamura AC, Sassella F, Santini A, et al (2003) Intramuscular preparations of antipsychotics: uses of relevance in clinical practice. Drugs 63: 493-512. (Pubitemid 36337728)
5. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA.
6. Andrezina R, Josiassen RC, Marcus RN, et al (2006) Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berlin) 188: 281-92. (Pubitemid 44387456)
7. Battaglia J, Lindborg SR, Alaka K, et al (2003) Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine 21: 192-8. (Pubitemid 36734681)
8. Battaglia J (2004) Intramuscular olanzapine: treating acute agitation in psychosis and bipolar mania. Current Psychiatry 3: 76-8.
9. Battaglia J (2005) Pharmacologic management of acute agitation. Drugs 65: 1207-22.
10. Bellnier TJ (2002) Continuum of care: stabilizing the acutely agitated patient. American Journal of Health-system Pharmacy 59 (suppl 5): s12-8.
11. Bristol-Myers Squibb (2003) Aripiprazole (Abilify) Package Insert. Bristol- Myers Squibb.
12. Buckley PF, Noffsinger SG, Smith DA, et al (2003) Treatment of the psychotic patient who is violent. Psychiatric Clinics of North America 26: 231-72. (Pubitemid 36384355)
13. Burris KD, Molski TF, Xu C, et al (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 302: 381-9. (Pubitemid 34680462)
14. Canas F (2007) Management of agitation in the acute psychotic patient: efficacy without excessive sedation. European Neuropsychopharmacology 17 (suppl 2): s108-14.
15. Chengappa KNR, Goldstein JM, Greenwood M, et al (2003) A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clinical Therapeutics 25: 530-41. (Pubitemid 36286918)
16. Citrome L (2004a) New treatments for agitation. Psychiatric Quarterly 75: 197-213.
17. Citrome L, Brook S, Warrington L, et al (2004b) Ziprasidone versus haloperidol for the treatment of agitation. Annals of Emergency Medicine 44 (suppl): S22.
18. Citrome L (2007) Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Journal of Clinical Psychiatry 68: 1876-85.
19. Cohen-Mansfield J (1986) Agitated behavior in the elderly: a conceptual review. Journal of the American Geriatrics Society 34: 711-21.
20. Corrigan JD (1989) Development of a scale for assessment of agitation following traumatic brain injury. Journal of Clinical and Experimental Neuropsychology 11: 261-77.
21. Currier GW, Allen MH (2000) Physical and chemical restraint in the psychiatric emergency service. Psychiatric Services 51: 717-9. (Pubitemid 30354226)
22. Currier GW, Simpson GM (2001) Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry 62: 153-7. (Pubitemid 32270087)
23. Currier G, Allen MH, Bunney EB, et al (2004a) Novel therapies for treating acute agitation. Journal of Emergency Medicine 27 (suppl 1): S13-8.
24. Currier GW, Chou JCY, Feifel D, et al (2004b) Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. Journal of Clinical Psychiatry 65: 386-94.
25. Currier G, Trenton AJ, Walsh PG, et al (2006a) A pilot, open-label safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. Journal of Psychiatric Practice 12: 223-8. (Pubitemid 44180545)
26. Currier GW, Medori (2006b) Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. Journal of Psychiatric Practice 12: 30-40.
27. Currier GW, Citrome LL, Zimbroff DL, et al (2007) Intramuscular aripiprazole in the control of agitation. Journal of Psychiatric Practice 3: 159-69. (Pubitemid 46809448)
28. Daniel DG, Potkin SG, Reeves KR, et al (2001) Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berlin) 155: 128-34. (Pubitemid 32417820)
29. Daniel DG, Zimbroff DL, Swift RH, et al (2004) The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. International Clinical Psychopharmacology 19: 9-15. (Pubitemid 38114618)
30. De Fruyt, Demyttenaere K (2004) Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. European Psychiatry 19: 243-9.
31. Downey LV, Zun LS, Gonzales SJ (2007) Frequency of alternative to restraints and seclusion and uses of agitation reduction techniques in the emergency department. General Hospital Psychiatry 29: 470-4. (Pubitemid 350088158)
32. DuBuske LM (1999) Second-generation antihistamines: the risk of ventricular arrhythmias. Clinical Therapeutics 21: 281-95.
33. Eli Lilly (2006) Olanzapine (Zyprexa) US Prescribing Information. Eli Lilly.
34. Eli Lilly (2008) Highlights of Prescribing Information: Zyprexa (Olanzapine) Tablets, Zyprexa Zydis (Olanzapine) Orally Disintegrating Tablets, Zyprexa Intramuscular (Olanzapine) for Injection. Product Information, Revised March 10, 2008. Eli Lilly (http://pi.lilly.com/us/zyprexa-pi.pdf).
35. Escobar R, San L, Pérez V, et al (2008) Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results form NATURA study [in Spanish]. Actas Españolas de Psiquiatría 36: 151-7.
36. Expert Consensus Panel for Behavioral Emergencies (2005) The expert consensus guideline series. Treatment of behavioral emergencies 2005. Journal of Psychiatric Practice 11 (suppl 1): 5-108.
37. Fisher WA (1994) Restraint and seclusion: a review of the literature. American Journal of Psychiatry 15: 1584-91.
38. Foster S, Kessel J, Berman ME, et al (1997) Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology 12: 175-9. (Pubitemid 27283327)
39. Ganesan ML, Bilsker D, Khanbhai I (2005) Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. International Journal of Psychiatry in Clinical Practice 9: 199-203. (Pubitemid 41499389)
40. Glassman AH (2001) Antipsychotic drugs: prolonged QTc interval, Torsades de pointes, and sudden death. American Journal of Psychiatry 158: 1774-82.
41. Greenblatt DJ, Blaskovich PD, Nuwayser ES, et al (2005) Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. Journal of Pharmacology 45: 1288-93. (Pubitemid 41513052)
42. Hatta K, Kawabata T, Yoshida K, et al (2008) Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. General Hospital Psychiatry 30: 367-71. (Pubitemid 351862316)
43. Karagianis JL, Dawe IC, Thakur A, et al (2001) Rapid tranquilization with olanzapine in acute psychosis: a case series. Journal of Clinical Psychiatry 62 (suppl 2): 12-6. (Pubitemid 32154135)
44. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13: 261-76. (Pubitemid 18039085)
45. Kinon BJ, Stauffer VL, Kollack-Walker S, et al (2008) Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Psychopharmacology 28: 601-7.
46. Kopecky HJ, Kopecky CR, Yudofsky SC (1998) Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients. Psychiatric Quarterly 69: 301-23. (Pubitemid 28460423)
47. Lejeune J, Larmo I, Chrzanowski W, et al (2004) Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. International Clinical Psychopharmacology 19: 259-69. (Pubitemid 39141942)
48. Leonard BE (1992) Fundamentals of Psychopharmacology. John Wiley & Sons.
49. Lesem MD, Zajecka JM, Swift RH, et al (2001) Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Journal of Clinical Psychiatry 62: 12-8. (Pubitemid 32154312)
50. Lindenmayer J (2000) The pathophysiology of agitation. Journal of Clinical Psychiatry 61 (suppl 14): 5-10.
51. Marder SR (2006) A review of agitation in mental illness: treatment guidelines and current therapies. Journal of Clinical Psychiatry 67 (suppl 10): 13-21.
52. McAllister-Williams RH, Ferrier IN (2002) Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. British Journal of Psychiatry 180: 485-9. (Pubitemid 34596797)
53. McCue RE, Waheed R, Urcuyo L, et al (2006) Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry 189: 433-40. (Pubitemid 44683176)
54. Meehan K, Zhang F, David S, et al (2001) A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology 21: 389-97. (Pubitemid 32673028)
55. Mendelowitz A (2004) The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Annals of Clinical Psychiatry 16: 145-54.
56. Mendoza R, Djenderedjian AH, Adams J, et al (1987) Midazolam in acute psychotic patients with hyperarousal. Journal of Clinical Psychiatry 48: 291-2. (Pubitemid 17108410)
57. Miller DD (2004) Atypical antipsychotics: sleep, sedation, and efficacy. Primary Care Companion to the Journal of Clinical Psychiatry 6 (suppl 2): 3-7.
58. Mohr P, Pecenák J, Svestka J, et al (2005) Treatment of acute agitation in psychotic disorders. Neuroendocrinology Letters 26: 327-35. (Pubitemid 41518772)
59. Montout C, Casadebaig F, Lagnaoui R, et al (2002) Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research 57: 147-56. (Pubitemid 35240016)
60. National Collaborating Centre for Nursing and Supportive Care (2005) Violence: The Short-term Management of Disturbed/Violent Behaviour in In-Patient Psychiatric Settings and Emergency Departments (Clinical Practice Guideline 25). National Institute for Health and Clinical Excellence (http://www.nice.org. uk/nicemedia/live/10964/29719/29719.pdf).
61. Ness G, House A, Ness AR (2000) Aggression and violent behaviour in general practice: population based survey in the north of England. BMJ 320: 1447-8. (Pubitemid 30311677)
62. Pereira S, Paton C, Walkert LM, et al (2005) Treatment of acute behavioural disturbance: a UK national survey of rapid tranquillisation. Journal of Psychiatric Intensive Care 1: 84-8.
63. Petit J (2005) Management of the acutely violent patient. Psychiatric Clinics of North America 28: 701-11.
64. Pfizer (2009) Highlights of Prescribing Information: Geodon (Ziprasidone HCL) Capsules, Geodon (Ziprasidone Mesylate) Injection for Intramuscular Use. Product Information, Revised May (http://www.pfizer.com/files/products/uspi- geodon.pdf).
65. Preval H, Klotz SG, Southard R, et al (2005) Rapid-acting intramuscular ziprasidone in the psychiatric emergency service: a naturalistic violence. General Hospital Psychiatry 27: 140-4. (Pubitemid 40348779)
66. Raja M, Azzoni A (2001) Novel antipsychotics and acute dystonic reactions. International Journal of Neuropsychopharmacology 4: 393-7. (Pubitemid 33151683)
67. Raja M, Azzoni A (2003) Comparison of three antipsychotics in the emergency room setting. Human Psychopharmacology 18: 447-52. (Pubitemid 37038340)
68. Ray WA, Meredith S, Thapa PB, et al (2001) Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 58: 1161-7. (Pubitemid 33121508)
69. Tran-Johnson TK, Sack DA, Marcus RN, et al (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind placebo controlled trial. Journal of Clinical Psychiatry 68: 111-9. (Pubitemid 46220132)
70. TREC Collaborative Group (2003) Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 327: 708-11.
71. Tulloch KJ, Zed PJ (2004) Intramuscular olanzapine in the management of acute agitation. Annals of Pharmacotherapy 38: 2128-35. (Pubitemid 40169386)
72. Van Schaick EA, Lechat P, Remmerie BM, et al (2003) Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clinical Therapeutics 25: 1687-99. (Pubitemid 36801942)
73. Villari V, Rocca P (2008) Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32: 405-13. (Pubitemid 351210624)
74. Wise R (2000) New restraint standards will change your practice. ED Management 12: 93-5.
75. Wright P, Birkett M, David SR, et al (2001) Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry 158: 1149-51. (Pubitemid 32623122)
76. Wright P, Meehan K, Birkett M, et al (2003) A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 25: 1420-8. (Pubitemid 36677285)
77. Yudofsky SC, Kopecky HJ, Kunik M, et al (1997) The Overt Agitation Severity Scale for the objective rating of agitation. Journal of Neuropsychiatry and Clinical Neurosciences 9: 541-8. (Pubitemid 28029747)
78. Zimbroff DL, Marcus RN, Manos G, et al (2007) Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. Journal of Psychopharmacology 27: 171-6. (Pubitemid 46594934)